
    
      This is a 3-part study to examine the efficacy, safety, tolerability, PK and PD of BIIB067.
      Part A is the single ascending dose (SAD) component of the study, Part B is the multiple
      ascending dose (MAD) component of the study and Part C is the fixed dose component of the
      study. Hence, the overall phase of development of the study is 1/2/3.

      Parts A and B were completed on 15-Jan-2019. In total, the study is estimated to enroll 183
      participants, with 99 in Part C.
    
  